Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.03), $0.01 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $4.57 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.